BERKELEY, Calif. and MAINZ, Germany - Mainz Biomed NV (NASDAQ:MYNZ), a company focused on early cancer detection diagnostics, has announced its return to compliance with Nasdaq's stockholders' equity ...

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements ...

Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information About Mainz Biomed NV Mainz Biomed develops market-ready molecular genetic diagnostic ...

The FDA granted marketing clearances for infectious disease tests, updates to a digital pathology system, and immunoassays for chronic diseases.

Statistics Canada has always provided its users with the most recent data available, but after consulting some of its expert data users, the agency identified a need for real-time data—or vintage data ...

AArly DETECT 2 feasibility study designed to validate earlier results on advanced adenomas over a large population of average ...

Real-Time PCR (qPCR) market Insights: Used extensively in diagnostics, life sciences, and environmental testing ...